Finance 20 May 2026 - 21 May 2026

Heritage Financial Stock Is Quiet Now, but One Bank Margin Test Could Decide What Comes Next
·····

Heritage Financial Stock Is Quiet Now, but One Bank Margin Test Could Decide What Comes Next

Heritage Financial Corp. shares closed at $27.25 Friday, down 0.33%, lagging bank sector gains as investors weighed the impact of its Olympic Bancorp acquisition. First-quarter net income was $18.9 million, with net interest margin rising to 3.96%. Management expects cost savings after completing systems integration in Q3. A recent SEC filing disclosed a cybersecurity incident involving an internal file-share server.
May 30, 2026
Star Bulk Stock Gets a Dividend Jolt as SBLK Cash Returns Take Center Stage
····

Star Bulk Stock Gets a Dividend Jolt as SBLK Cash Returns Take Center Stage

Star Bulk Carriers reported first-quarter net profit of $58.5 million, up from $0.5 million a year earlier, and raised its quarterly dividend to $0.50 per share. Shares closed at $26.69, up 2.34%, and held steady in pre-market trade. Voyage revenue rose to $281.2 million. The results follow Diana Shipping’s push to acquire Genco, with Star Bulk set to buy 16 Genco vessels if the deal closes.
May 21, 2026
Akebia Shares Bounce 12% After Volatile Session
····

Akebia Shares Bounce 12% After Volatile Session

Akebia Therapeutics shares rose 12% to $1.01 in late trading Wednesday, rebounding from a two-day slide on heavy volume. The move followed first-quarter results showing Vafseo revenue climbed to $15.8 million while Auryxia sales fell to $36.2 million. Total revenue dropped to $53.5 million, with a net loss of $9.1 million. Investors weighed Vafseo’s growth against declining Auryxia sales and generic competition.
May 21, 2026
BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3
····

BioVie Stock Pops After Parkinson’s Trial Milestone. The Real Test Comes in Q3

BioVie shares closed at $1.35, up 3.05%, after the company said the last patient visit in its SUNRISE-PD Phase 2 Parkinson’s trial was completed. The company expects topline data in Q3 2026 for its experimental drug bezisterim. Trading volume was 19,735 shares, well below average. The trial enrolled 57 early-stage patients and tested motor and non-motor outcomes.
May 21, 2026
NAII Stock Gains Despite Wider Loss, Cash Still the Focus
····

NAII Stock Gains Despite Wider Loss, Cash Still the Focus

Natural Alternatives International shares rose 1.8% to $2.59 after reporting a fiscal third-quarter loss of $4.3 million on $35.5 million in revenue. Gross margin fell to 1.1% as sales rose 23%. The company replaced Wells Fargo debt with an $11 million term loan and a $20 million working-capital line from Legacy Corporate Lending. Management plans to sell its headquarters for added liquidity.
May 21, 2026
HeartCore Cash Concerns Leave HTCR Shares Flat
····

HeartCore Cash Concerns Leave HTCR Shares Flat

HeartCore Enterprises shares closed at $2.70 Wednesday, up 2 cents, with thin volume of 23,040 shares. The company reported a 40.5% drop in quarterly revenue and an 86.4% decline in gross profit. Its 10-Q cited “substantial doubt” about its ability to continue as a going concern, with $0.8 million in cash and a $15.6 million accumulated deficit at March 31. No new corporate announcements were posted.
May 20, 2026
Sunrun Stock Jumps as Solar Names Rally; Cash Flow in the Spotlight
····

Sunrun Stock Jumps as Solar Names Rally; Cash Flow in the Spotlight

Sunrun Inc. shares closed at $13.69 Wednesday, up 3.9% on heavy volume, as solar stocks rallied broadly. First-quarter revenue rose 43% to $722.2 million, but the company reported negative Cash Generation of $59 million. Sunrun’s storage attachment rate hit a record 73%. The company warned that higher interest rates and policy changes could impact financing and costs.
May 20, 2026
Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame
····

Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame

Esperion Therapeutics shares held at $3.13 late Wednesday, just below Archimed’s $3.16-a-share cash offer, as investors assessed closing and milestone risks in the $1.1 billion take-private deal. The stock saw volume above 7 million shares. The merger includes a contingent value right tied to future drug sales. Esperion’s first-quarter revenue rose to $80.1 million, with a net loss narrowing to $25.2 million.
May 20, 2026
Ituran Shares Tick Higher Ahead of Results
····

Ituran Shares Tick Higher Ahead of Results

Ituran Location and Control shares rose 0.39% to $57.17 on Nasdaq Wednesday, ahead of its first-quarter results due May 26. The company, valued at $1.14 billion, last reported quarterly revenue of $93.5 million and 77 cents EPS, with 76% of revenue from subscriptions. Analyst targets range from $55 to $70. The stock remains below its 52-week high of $62.31.
May 20, 2026
Fifth Era Stock Little Changed as Traders Watch $10 Billion Metals Deal
····

Fifth Era Stock Little Changed as Traders Watch $10 Billion Metals Deal

Fifth Era Acquisition Corp I Class A shares traded at $10.37, down 0.1% in thin Nasdaq trading Wednesday, near the $10.43 per-share trust value reported March 31. The SPAC expects to close its merger with strategic metals firm Miotal in the second half of 2026, pending approvals. CFO Christopher Linn resigned May 8, replaced by Christopher Nelson. Fifth Era reported $1.29 million net income for the March quarter, with no operating revenue.
May 20, 2026
Friedman Industries Stock Trades Lower Ahead of Dividend, Steel Sector Up
····

Friedman Industries Stock Trades Lower Ahead of Dividend, Steel Sector Up

Friedman Industries shares fell 0.6% to $20.60 Wednesday afternoon, underperforming rising steel and small-cap indexes. No new company news appeared ahead of its scheduled $0.04-per-share dividend payment on May 22. Volume was 10,229 shares, with a market value near $146.5 million. The company last reported quarterly net earnings of $3 million on $168 million in sales.
May 20, 2026
Immutep Shares Drop as Investors Face Trial Setback, Lawsuit Date and Nasdaq Alert
····

Immutep Shares Drop as Investors Face Trial Setback, Lawsuit Date and Nasdaq Alert

Immutep Ltd’s Nasdaq ADRs fell about 5% Wednesday as new law-firm notices highlighted litigation over its failed lung-cancer trial. The stock traded at $0.4778, below the $1 minimum required by Nasdaq, which warned the company on April 30. A securities class-action lawsuit was filed covering ADR purchases from March 2025 to March 2026. Immutep reported A$110.6 million in cash at March 31.
May 20, 2026
Krispy Kreme Stock Pops as DNUT’s Turnaround Faces Its Next Test
·····

Krispy Kreme Stock Pops as DNUT’s Turnaround Faces Its Next Test

Krispy Kreme shares climbed 4.4% to $3.35 Wednesday, outpacing major indexes as McDonald’s traded flat. The company reported first-quarter net revenue of $367 million, down 2.2%, with a narrowed net loss of $22.7 million and adjusted EBITDA up 38% to $33.1 million. Krispy Kreme ended Q1 with 15,125 global points of access, down 15.9% from a year earlier. Recent promotions included free doughnuts for graduates and the return of a lemon-filled item.
May 20, 2026
Oportun Shares Gain on Profit Run, Questions Remain Around Credit Losses
·······

Oportun Shares Gain on Profit Run, Questions Remain Around Credit Losses

Oportun Financial shares rose 2.9% to $5.40 Wednesday afternoon, near their intraday high, on volume of about 191,000 shares and no recent company news. Peer lenders and small-cap benchmarks also gained. Oportun’s latest filings show first-quarter net income of $2.3 million and a net charge-off rate rising to 12.7%. The company plans a new credit model and risk-based pricing as delinquency rates edge down.
May 20, 2026
NervGen Stock Climbs with Trial Approaching, Cash Burn Still a Focus
····

NervGen Stock Climbs with Trial Approaching, Cash Burn Still a Focus

NervGen Pharma shares climbed nearly 4% to $3.70 on Nasdaq after the company announced it had reached agreement with the FDA to begin its late-stage RESTORE trial for NVG-291 in chronic tetraplegia. The company reported C$16.56 million in cash at March 31, enough to fund operations through Q2 2026, and said additional capital will be needed for the Phase 3 trial.
May 20, 2026
Aurora Shares Bounce, but Traders Eye SEC Filing
····

Aurora Shares Bounce, but Traders Eye SEC Filing

Aurora shares rose 2.7% to $7.13 in midday trading Wednesday after Greylock-linked holders tied to director Reid Hoffman sold about 5.85 million shares last week at prices averaging $7.81 and $7.51. The stock rebounded after a two-day slide, with volume near 9.6 million shares and a market value around $13.9 billion. Aurora posted Q1 revenue of $1 million and a net loss of $223 million.
May 20, 2026
1 … 24 25 26 27 28 … 212

Stock Market Today

  • 6 Key Numbers to Value Pro Medicus Ltd (ASX:PME) Shares
    May 30, 2026, 1:15 AM EDT. Pro Medicus Ltd (ASX:PME), a radiology IT software provider, has seen its share price fall 40.59% since the start of the year. The company posted $162 million in annual revenue with a 33.4% compound annual growth rate over three years. Its gross margin of 99.8% highlights operational strength. PME reported a profit of $83 million last year, growing at 39.0% CAGR over three years. Financial health is robust, with net debt of negative $153 million, indicating more cash than debt, and a low debt-to-equity ratio of 1.1%. The return on equity (ROE) stands at 50.7%, reflecting efficient capital use. These metrics provide key insights to evaluate PME's share performance this year amid market volatility.